Objective: to develop a multiple-endpoint monitoring system in order to assess and minimize long term risks in hospital nurses exposed to antiblastic drugs. Design: molecular epidemiology study. Setting: S. Orsola-Malpighi Hospital in Bologna, Italy nurses exposed to antiblastic drugs. Participants: 50 exposed subjects (8 males and 42 females) and 50 unexposed individuals (8 males and 42 females) matched for age and smoking habits. Main outcome measures: urinary markers of exposure; Heat Shock Proteins (HSPs) 27, 70, 90, 110; immunological biomarkers in peripheral blood lymphocytes; apoptosis, cell-cycle analysis G1-S-G, typization of Natural Killer cells (NK) and receptors for IL-2 in peripheral blood lymphocytes; micronuclei: frequency in peripheral blood lymphocytes and in exfoliated buccal mucosa cells; activation of specific oncogenes (bax, bcl2, b-actin). Results: 19/50 subjects showed urinary antiblastic drugs levels (3 subjects MTX, 11 subjects CP, 5 subjects MTX and CP). No statistically significant differences were observed in all the considered biomarkers between the exposed and control groups. Conclusion: this biomonitoring study doesn’t evidence any early significant effect associated to the exposure to antiblastic drugs.
BIOMONITORING OF NURSES OCCUPATIONALLY EXPOSED TO ANTINEOPLASTIC DRUGS: THE IMEPA PROJECT
NUCCI, MARIA CONCETTA;COLACCI, ANNAMARIA;GRILLI, SANDRO;CHIOZZOTTO, DANIELA;HORN, WOLFANGO;RISI, ALESSANDRO;SILINGARDI, PAOLA;VACCARI, MONICA;VIOLANTE, FRANCESCO SAVERIO
2005
Abstract
Objective: to develop a multiple-endpoint monitoring system in order to assess and minimize long term risks in hospital nurses exposed to antiblastic drugs. Design: molecular epidemiology study. Setting: S. Orsola-Malpighi Hospital in Bologna, Italy nurses exposed to antiblastic drugs. Participants: 50 exposed subjects (8 males and 42 females) and 50 unexposed individuals (8 males and 42 females) matched for age and smoking habits. Main outcome measures: urinary markers of exposure; Heat Shock Proteins (HSPs) 27, 70, 90, 110; immunological biomarkers in peripheral blood lymphocytes; apoptosis, cell-cycle analysis G1-S-G, typization of Natural Killer cells (NK) and receptors for IL-2 in peripheral blood lymphocytes; micronuclei: frequency in peripheral blood lymphocytes and in exfoliated buccal mucosa cells; activation of specific oncogenes (bax, bcl2, b-actin). Results: 19/50 subjects showed urinary antiblastic drugs levels (3 subjects MTX, 11 subjects CP, 5 subjects MTX and CP). No statistically significant differences were observed in all the considered biomarkers between the exposed and control groups. Conclusion: this biomonitoring study doesn’t evidence any early significant effect associated to the exposure to antiblastic drugs.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
